Career Strategy
Building a U.S. Career as a Polish biotech CEO — August 2025
Everything you need to know about the latest changes and how they affect your O-1 strategy.
The O-1A pathway for Polish biotech executives seeking US market entry
Polish biotech executives seeking to establish or lead organizations in the United States occupy a favorable position in the O-1A classification framework, though the path requires deliberate evidence construction rather than automatic translation of European credentials. The O-1A visa for individuals of extraordinary ability in the sciences, education, business, or athletics captures the dual professional identity of a biotech CEO precisely: the scientific foundation that underlies most biotech executive careers positions the beneficiary within the sciences dimension, while the business leadership role adds the executive dimension that distinguishes a founding CEO from a researcher. Polish professionals in this space frequently have records that span both dimensions, and the petition strategy must decide which dimension to emphasize or whether to build across both.
Poland's biotech sector has developed significantly since the country's accession to the European Union, with research institutions including the Polish Academy of Sciences and universities in Warsaw, Krakow, Gdansk, and Wroclaw producing internationally published research in fields including oncology, genomics, and pharmaceutical chemistry. Polish biotech founders have access to EU Horizon Europe funding, EIC Accelerator grants, and the European Research Council framework that provides a foundation of externally validated research and commercial credibility. These funding mechanisms — competitive, reviewed by international expert panels, and publicly documented — create the kind of externally anchored evidence that O-1A adjudicators find persuasive when the petition's connection to US market activities is clearly articulated.
The practical starting point for a Polish biotech CEO pursuing O-1A is an honest assessment of the evidence record against the eight enumerated O-1A criteria in 8 C.F.R. § 214.2(o)(3)(iii). Criteria that are frequently accessible for biotech executives include original contributions of major significance to the field (through peer-reviewed research and patent records), high salary or remuneration relative to peers in the field, critical role in distinguished organizations (as founding CEO or board-level leadership at recognized biotech companies), and published scholarly material (through peer-reviewed publications and co-authored industry reports). The petition strategy should identify the three or more criteria with the strongest documentation and build the extraordinary ability narrative around that evidentiary foundation.
Original contributions in biotech: from EU research to US market relevance
The original contributions criterion under 8 C.F.R. § 214.2(o)(3)(iii)(B)(4) requires evidence of original scientific or scholarly contributions of major significance to the field. For a Polish biotech CEO whose career combines academic research and executive leadership, the contributions are typically documented through peer-reviewed publications in recognized biomedical journals — Nature Medicine, the Journal of Clinical Oncology, PLOS ONE, or equivalent venues depending on the specialty — combined with patent records that demonstrate the translation of research insights into protected intellectual property. The combination of academic publication and patent protection is particularly persuasive for O-1A adjudicators because it demonstrates both that the contribution was recognized by the scientific community as novel and that the contribution had sufficient commercial potential to warrant the expense and disclosure of patent prosecution.
The major significance element requires that the contribution have impact beyond the immediate research team. For biotech CEOs, major significance is best established through citation evidence — Google Scholar citation counts by independent researchers at other institutions — and through evidence that the research has influenced subsequent work in the field, been incorporated into clinical practice guidelines, or formed the basis for regulatory filings by the beneficiary's company or by third parties who licensed the underlying technology. Expert letters from recognized researchers at international institutions who can speak to the contribution's significance in the broader research community provide the qualitative assessment that citation counts and patent records supply quantitatively.
Polish biotech CEOs whose contributions are documented primarily in Polish-language publications or in European conference proceedings face an additional framing challenge in O-1A petitions: these venues may be unfamiliar to adjudicators who are more familiar with US and anglophone research ecosystems. The petition should include documentation of the publication venue's standing — impact factor data, indexing in Medline or PubMed, SCOPUS ranking within the relevant specialty — and should, where possible, supplement Polish-language publications with their international conference presentations or subsequent English-language derivative publications. Expert letters from internationally recognized researchers who can independently verify the significance of the work within the European and global biotech research community address the geographic familiarity gap directly.
High salary and compensation evidence for Polish biotech executives
The high salary criterion for Polish biotech CEOs requires the same multi-market benchmarking approach that applies in other international O-1A cases. Polish executive compensation in the biotech sector is structured differently from US biotech executive compensation: Polish biotech CEOs at early-stage companies frequently draw a combination of modest base salary and equity participation that is difficult to benchmark against annual salary data, while US biotech CEO compensation includes cash compensation, stock options, and performance-based bonuses that are documented in proxy filings for public companies. Demonstrating high compensation in the Polish market context requires Polish market-specific data, not direct comparison to US C-suite compensation benchmarks.
Compensation data for Polish biotech executives can be sourced from the Polish Association of Listed Companies executive remuneration surveys, PwC Poland and Deloitte Poland annual compensation reports for the life sciences sector, and the European Biotech Report that covers compensation benchmarks across European markets. Where the beneficiary's company has received investment from recognized venture capital funds — including funds in the EIC Accelerator or Horizon Europe portfolio — the investment valuation and the beneficiary's ownership stake can be documented as part of the total compensation analysis, converting the equity component to a documented economic value that supplements the cash compensation benchmark.
For the proposed US compensation, the petition should benchmark the offered salary against BLS OEWS data for chief executives (SOC 11-1011) in the biotechnology and pharmaceutical manufacturing sector in the relevant geographic market. US biotech CEO compensation at funded startups typically includes cash salary in the range documented in the BLS OEWS upper quartile for the occupation, plus equity participation structured through stock options or restricted stock units that vests over a defined period. The H-1B prevailing wage determination at Level IV for the proposed position — if secured from the Department of Labor — provides an additional government-issued benchmark that USCIS adjudicators recognize as establishing the wage's relationship to prevailing rates for the occupation.
Critical role in distinguished organizations across the career
The critical role criterion for a Polish biotech CEO typically presents two strands of evidence: leadership of the beneficiary's own company, and board or advisory roles at other recognized organizations in the biotech ecosystem. The founder-CEO role at the beneficiary's company satisfies the critical capacity element — the CEO is, by definition, the person whose strategic decisions determine the direction and survival of the organization — but the distinction element requires documentation that the organization itself has achieved a recognized level of standing in the field. For an early-stage Polish biotech company, distinction is typically established through funding from recognized sources, regulatory milestones, press coverage in recognized biotech trade publications, and partnerships with established pharmaceutical companies or research institutions.
Advisory board and scientific advisory committee roles at recognized institutions — major research universities, industry associations such as the Polish Chamber of Pharmaceutical Industry, European Biopharmaceutical Enterprises, and equivalent bodies — satisfy the critical role criterion at those organizations' level of distinction. The key distinction between a nominal advisory role and a genuine critical role is the scope of the advisory function: a scientific advisory committee member who attends quarterly meetings without specific deliverables is in a less critical role than one who chairs a technical subcommittee responsible for evaluating research proposals or advising on a specific regulatory or product development question. Documentation of the specific advisory function — the scope of the advisory work, the decisions informed by it, and the organization's own description of the advisory committee's role — distinguishes credible from nominal advisory evidence.
Board membership at portfolio companies of recognized venture capital funds in the European biotech ecosystem — EQT Life Sciences, Sofinnova Partners, Forbion, Gimv — provides another strand of critical role evidence if the beneficiary has been appointed to portfolio company boards in a capacity that reflects recognized expertise in the relevant therapeutic area or business domain. Board appointments at funded biotech companies are made by investors who have conducted due diligence on the appointee's credentials, and the appointment document — a board appointment letter or corporate resolution — combined with the fund's documented standing in the European biotech investment community, provides the petitioner with both the critical capacity documentation and the distinguished organization documentation for that strand of the criterion.
Memberships, judging, and publications in European biotech contexts
The memberships criterion under 8 C.F.R. § 214.2(o)(3)(iii)(B)(2) requires membership in associations in the field that require outstanding achievement of their members as judged by recognized national or international experts. For Polish biotech executives, memberships that satisfy this criterion include fellowship or membership in European learned societies with documented membership criteria — the European Molecular Biology Organization, the Academy of Medical Sciences in European contexts, national academies with documented extraordinary achievement criteria — and membership in industry organizations that are selective rather than open-enrollment. Not all professional membership organizations satisfy this criterion; the petition must document the organization's membership criteria and how they require outstanding achievement rather than merely professional status or fee payment.
The judging criterion is frequently accessible for biotech CEOs through grant review panel service. EU Horizon Europe, the European Research Council, and national funding bodies including Poland's National Science Centre (NCN) and the National Centre for Research and Development (NCBR) operate peer review panels composed of recognized experts in the relevant scientific area. Service on these review panels — documented through the funding body's appointment letter, published reviewer acknowledgment in funded projects where applicable, and any report of panel service in the beneficiary's CV — satisfies the judging criterion if the panel has sufficient standing in the field. The ERC's reviewer selection process is particularly well-documented and internationally recognized, and ERC panel service is a strong judging criterion evidence item for scientific CEOs.
Published scholarly material in peer-reviewed venues addresses the publications criterion under 8 C.F.R. § 214.2(o)(3)(iii)(B)(5). For biotech CEOs who have transitioned primarily into executive roles, publication records from the research phase of their careers remain relevant and should be documented comprehensively, including publication venue standing and citation data. Biotech CEOs who continue to publish — as co-author on company research, as authors of industry commentary in recognized journals such as Nature Biotechnology, Cell Chemical Biology, or Drug Discovery Today — have stronger publications criterion evidence than those whose publication record ends at the point of their executive transition. Encouraging continued publication, even in the form of industry commentary or collaborative research, is one concrete way practitioners can strengthen a biotech CEO's O-1A evidence during the pre-filing period.
Long-term career strategy: from O-1A to a US green card
O-1A approval is typically the first step in a longer US immigration strategy for Polish biotech CEOs whose goal is permanent US market presence. The O-1 visa authorizes nonimmigrant status, not permanent residence, and it must be renewed periodically — typically in three-year increments with extensions in one-year increments where continued O-1 employment can be demonstrated. For biotech CEOs who are building a US company rather than temporarily representing a foreign employer, the O-1 period should be used deliberately to build the permanent residence case in parallel, targeting the EB-1A extraordinary ability immigrant petition or, where an employer relationship supports it, the EB-1B outstanding researcher or EB-1C multinational executive petition.
The EB-1A immigrant petition uses the same extraordinary ability standard as O-1A and the same enumerated criteria, but it establishes permanent residence rather than temporary status. Polish biotech CEOs who have successfully made the O-1A case have, in principle, established the evidentiary foundation for an EB-1A petition — but the EB-1A standard, while nominally identical, is applied at a somewhat higher threshold in practice because the stakes of permanent residence are greater than those of a nonimmigrant status. Practitioners who represent O-1A clients should advise them to continue building the petition evidence record during the O-1 period — accumulating additional publications, citations, recognitions, and compensation benchmarks — rather than assuming the O-1A record is sufficient for EB-1A without further development.
For Polish biotech CEOs who are US subsidiaries of Polish parent companies, the EB-1C multinational executive petition offers an alternative permanent residence pathway that does not require the extraordinary ability showing of EB-1A. The EB-1C requires that the beneficiary have been employed abroad by the petitioning company's parent, subsidiary, or affiliate for at least one of the three years preceding the petition, and that the proposed US role be in a managerial or executive capacity. For a CEO who has led the Polish parent company and is moving to lead its US subsidiary, the EB-1C pathway may be more straightforward than the EB-1A, and the two pathways can be pursued simultaneously if the extraordinary ability record is strong enough to support EB-1A independently. Practitioners should evaluate both options at the outset of the O-1A case planning process.